| Giving AXL the axe: targeting AXL in human malignancy CM Gay, K Balaji, LA Byers British journal of cancer 116 (4), 415-423, 2017 | 301 | 2017 |
| Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer F Meric-Bernstam, AM Johnson, EEI Dumbrava, K Raghav, K Balaji, ... Clinical Cancer Research 25 (7), 2033-2041, 2019 | 276 | 2019 |
| Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses EJ Gillespie, CLC Ho, K Balaji, DL Clemens, G Deng, YE Wang, ... Proceedings of the National Academy of Sciences 110 (50), E4904-E4912, 2013 | 99 | 2013 |
| Molecular genetics and cellular events of K-Ras-driven tumorigenesis GG Jinesh, V Sambandam, S Vijayaraghavan, K Balaji, S Mukherjee Oncogene 37 (7), 839-846, 2018 | 94 | 2018 |
| AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers K Balaji, S Vijayaraghavan, L Diao, P Tong, Y Fan, JPW Carey, TN Bui, ... Molecular Cancer Research 15 (1), 45-58, 2017 | 88 | 2017 |
| RIN1 orchestrates the activation of RAB5 GTPases and ABL tyrosine kinases to determine the fate of EGFR K Balaji, C Mooser, CM Janson, JM Bliss, H Hojjat, J Colicelli Journal of cell science 125 (23), 5887-5896, 2012 | 81 | 2012 |
| Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional … EEI Dumbrava, K Balaji, K Raghav, K Hess, M Javle, M Blum-Murphy, ... JCO Precision Oncology 3, 1-12, 2019 | 38 | 2019 |
| RIN1 regulates cell migration through RAB5 GTPases and ABL tyrosine kinases K Balaji, J Colicelli Communicative & integrative biology 6 (5), e25421, 2013 | 19 | 2013 |
| The RAB5‐GEF Function of RIN1 Regulates Multiple Steps During Listeria monocytogenes Infection K Balaji, CT French, JF Miller, J Colicelli Traffic 15 (11), 1206-1218, 2014 | 11 | 2014 |
| Identification of actionable genomic alterations using circulating cell-free DNA NS Sánchez, MP Kahle, AM Bailey, C Wathoo, K Balaji, ME Demirhan, ... JCO Precision Oncology 3, 1-10, 2019 | 8 | 2019 |
| Direct costs of carcinoid syndrome diarrhea among adults in the United States A Dasari, VN Joish, R Perez-Olle, S Dharba, K Balaji, DM Halperin World journal of gastroenterology 25 (47), 6857, 2019 | 7 | 2019 |
| Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea A Dasari, VN Joish, R Perez-Olle, S Dharba, K Balaji, DM Halperin Expert Review of Pharmacoeconomics & Outcomes Research 20 (5), 507-511, 2020 | 5 | 2020 |
| Impact of #ASCO Twitter impressions on the oncology community. G Morgan, TK Choueiri, R Patel, K Balaji, V Subbiah Journal of Clinical Oncology 39 (15_suppl), 11039-11039, 2021 | 4 | 2021 |
| Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors EI Dumbrava, K Balaji, K Raghav, M Javle, M Blum-Murphy, B Sajan, ... Molecular Cancer Therapeutics 17 (1), 2018 | 3 | 2018 |
| PCN113 Direct and indirect costs associated with carcinoid syndrome diarrhea A Dasari, V Joish, R Perez-Olle, S Dharba, K Balaji, DM Halperin Value in Health 22, S77, 2019 | 1 | 2019 |
| Identification of actionable genomic alterations utilizing cfDNA. NS Sanchez, AM Bailey, C Wathoo, K Balaji, ME Demirhan, D Yang, ... Journal of Clinical Oncology 36 (15_suppl), 12110-12110, 2018 | | 2018 |
| Abstract A167: Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors E Ileana Dumbrava, K Balaji, K Raghav, M Javle, M Blum-Murphy, ... Molecular Cancer Therapeutics 17 (1_Supplement), A167-A167, 2018 | | 2018 |
| Identification of biomarkers of AXL-mediated drug resistance in head and neck squamous cell carcinoma K Balaji, R Cardnell, L Diao, P Tong, M Mak, YH Fan, F Masrorpour, ... Cancer Research 75 (15_Supplement), 3579-3579, 2015 | | 2015 |
| Neutrophil Elastase plays a key role in epithelial-mesenchymal transition and metastasis in triple-negative breast cancers K Balaji, CH Su, S Akli, KK Hunt, K Keyomarsi Cancer Research 75 (15_Supplement), 1422-1422, 2015 | | 2015 |
| The RAS Effector RIN1 Modulates Endocytosis via Activation of RAB5 GTPases and ABL Tyrosine Kinases K Balaji University of California, Los Angeles, 2014 | | 2014 |
